At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 256 enrolled
Drug / intervention
simvastatin (+) ezetimibe +1 moredrug
Likely dose
simvastatin (+) ezetimibe 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Open Label Study to Evaluate the Lipid Lowering Efficacy and Safety of Vytorin® 10/20 vs. Atorvastatin 10mg in Hypercholesterolemia Patients With Metabolic Syndrome in Korea
In Brief
A Phase 3 clinical trial evaluating simvastatin (+) ezetimibe and Comparator: atorvastatin for Hypercholesterolemia. Completed, enrolled 256 participants.
Detailed Summary
Prevalence of metabolic syndrome in korea is increasing. There is no clinical trial targeting on such increasing populations like metabolic syndrome patients with Vytorin® in korea. Therefore this trial will help evaluate the lipid lowering effect of Vytorin® in asian population with metabolic syndrome.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypercholesterolemia
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2007
First PostedJul 2007
Primary CompletionAug 2008
TodayJul 2026
First PostedJul 4, 2007
Enrollment StartJul 1, 2007
Primary CompletionAug 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 19.0 years ago
Interventions
simvastatin (+) ezetimibedrug
simvastatin (+) ezetimibe 10/20 mg ; tablet, once daily, 8 Weeks
Comparator: atorvastatindrug
atorvastatin 10 mg; tablet, once daily, 8 Weeks